Search

Your search keyword '"Masarone M."' showing total 317 results

Search Constraints

Start Over You searched for: Author "Masarone M." Remove constraint Author: "Masarone M."
317 results on '"Masarone M."'

Search Results

1. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?

2. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

3. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

4. Artificial Intelligence and liver: Opportunities and barriers

5. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort

6. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic Hepatitis C aged 75 years or older: A multicenter study

9. T.11.6 TREATMENT WITH GLECAPREVIR AND PIBRENTASVIR IS SAFE AND EFFECTIVE IN ITALIAN

10. Corrigendum to 'Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)' Nutrition, Metabolism and Cardiovascular diseases volume 32 issue 1 (2022) 1-16

11. Corrigendum to 'Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)' [Dig Liver Dis 54 (2022) 170-182]

12. An innovative annotation tool for selecting Regions of Interest (ROI) in contrast-enhanced imaging ultrasonography (CEUS) of Hepatocellular carcinoma (HCC).

13. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications

14. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

15. Italian association for the study of the liver position statement on SARS-CoV2 vaccination

17. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

22. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

23. VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS

24. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

26. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

27. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

29. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

30. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

32. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

33. T06.01.16 EVALUATION OF THE EFFECT DERIVED FROM SILYBIN WITH VITAMIN D AND 3 VITAMIN E ADMINISTRATION ON CLINICAL, METABOLIC, ENDOTHELIAL 4 DYSFUNCTION, OXIDATIVE STRESS PARAMETERS AND SEROLOGICAL WORSENING 5 MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS

34. T06.01.9 THE BISPHENOL A INDUCED WORSENING OF NON-ALCOHOLIC FATTY LIVER DISEASE: A CLINICAL STRATEGY TO ANTAGONIZE THE PROGRESSION OF THE DISEASE

36. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

37. HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era

47. Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort

49. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

50. No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: a real life data from South Italy. Hepatology 2014; 60 (S1): 695A-696A. Abstract. 1018

Catalog

Books, media, physical & digital resources